News
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk (NVO) stock draws mixed views from Wall Street analysts after the obesity drugmaker cut its 2025 outlook for the ...
In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
U.S.-listed shares of Novo Nordisk (NVO) fell sharply for a second straight day Wednesday, this time after Bank of America ...
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Despite a steep 65% drop from its all-time high of 145.99 a share in the prior 12 months, Novo Nordisk remains one of the most operationally sound businesses on the planet. As an investor, you are ...
Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback